Hyep Ivan 4
4 · Bicara Therapeutics Inc. · Filed Jan 26, 2026
Research Summary
AI-generated summary of this filing
Bicara Therapeutics (BCAX) CFO Hyep Ivan Exercises Options, Sells Shares
What Happened
Hyep Ivan, CFO of Bicara Therapeutics (BCAX), exercised 1,882 option shares at $3.79 per share (cost $7,132) on 2026-01-22 and sold the same 1,882 shares in the open market the same day for total gross proceeds of $34,162 (weighted average sale price $18.15). The transactions were executed pursuant to a Rule 10b5-1 trading plan.
Key Details
- Transaction dates: 2026-01-22 (exercise and sale). Filing date: 2026-01-26 (filed on time).
- Exercise: 1,882 shares at $3.79 each = $7,132 (code M).
- Sale: 1,882 shares at weighted avg $18.15 = $34,162 (code S); sale prices ranged $18.15–$18.18 (footnote). Reporting person will provide per-price breakdown on request.
- Net cash proceeds (gross sale minus exercise cost): ≈ $27,030.
- Shares owned after transaction: not specified in the filing.
- Notable footnotes: F1 — sale executed under a Rule 10b5-1 plan adopted Feb 13, 2025; F2 — sale price is weighted average and was executed in multiple trades; F3 — the underlying option vests in 16 equal quarterly installments following April 5, 2023.
Context
Because the shares were exercised and sold the same day, this effectively functioned as a cashless exercise followed by an open-market disposition. The use of a pre-established 10b5-1 plan indicates the sales were preplanned and routine rather than ad hoc.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-01-22$3.79/sh+1,882$7,132→ 147,237 total - Sale
Common Stock
[F1][F2]2026-01-22$18.15/sh−1,882$34,162→ 145,355 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F3]2026-01-22−1,882→ 65,462 totalExercise: $3.79Exp: 2033-04-05→ Common Stock (1,882 underlying)
Footnotes (3)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.15 to $18.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F3]The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.